Status:
RECRUITING
Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor
Lead Sponsor:
Baker Heart and Diabetes Institute
Conditions:
Heart Failure
Cognitive Impairment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk...
Eligibility Criteria
Inclusion
- Hospitalised with HF as primary or secondary diagnosis.
- At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge.
Exclusion
- Unable to provide written consent; requiring palliative care; or participating in another RCT
- Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with "true" CI, any patients with a repeated MoCA\>25 at 2 weeks post-discharge will be excluded.
- Terminal illness (eg. cancer) that may influence 12-month prognosis.
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT06088212
Start Date
July 1 2024
End Date
July 1 2026
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Menzies Institute for Medical Research
Hobart, Tasmania, Australia, 7000